番茄社区app

Tests do not appear to consistently influence risk classification or treatment decisions

Clinical utility of the FDA-approved test isn't clear, researchers say

Also in TTHealthWatch: U.S. drug prices under Medicare's price negotiation system

Nearly half of women with unusual or nonreportable cfDNA-sequencing results had cancer

Australian study explored screening for hundreds of genetic conditions

Testing could be useful for older women at higher risk

Long non-coding RNA implicated in human disease

Finding on HLA-DRB1*01:03 supports need for more and earlier genetic studies

FDA approves levacetylleucine (Aqneursa) for Niemann-Pick disease type C

Arimoclomol (Miplyffa) greenlit for ultra-rare genetic disorder

Health news and commentary gathered by 番茄社区app staff

In randomized study, guided site-specific therapy improved PFS versus empirical chemotherapy

Health news and commentary gathered by 番茄社区app staff